Mirela Cerghet
Neurology · Detroit, MINPI 1427171677
Payments from drug & device makers
What this record shows
This record is dominated by education: $205 of the $205 with a category attached, or 100.0%. EMD Serono, Inc. accounts for 81.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in MI, where the typical reported total is $1,115.
Across 4 payments — averaging $51.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$167
- Sandoz$38
Across 265 payments — averaging $14,262 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.6M
- Genentech, Inc.$689K
- Sanofi$78K
- Biogen$78K
- Roche Products Limited$72K
- F. Hoffmann-la Roche AG$72K
- plus $166K from 7 others
What the payments were for
- Education$205100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 3 | $167 |
| Sandoz | 1 | $38 |
How this compares
$205 in reported general payments places this provider in the 25th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 194 | $1,753,639 |
| CopaxoneGlatiramer Acetate | 193 | $1,156,119 |
| Glatiramer Acetate | 405 | $989,115 |
| RebifInterferon Beta-1a/Albumin | 54 | $545,105 |
| VumerityDiroximel Fumarate | 69 | $543,884 |
| TecfideraDimethyl Fumarate | 60 | $536,351 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 61 | $520,553 |
| EnspryngSatralizumab-Mwge | 24 | $455,770 |
| Dimethyl Fumarate | 317 | $294,804 |
| GilenyaFingolimod Hcl | 22 | $208,722 |
| BetaseronInterferon Beta-1b | 18 | $169,641 |
| GlatopaGlatiramer Acetate | 59 | $142,766 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $116,812 |
| Teriflunomide | 89 | $116,286 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $103,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $167 | $545,10554 claims |
| SandozGlatopa | $38 | $142,76659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 652 neurology providers in Michigan.
Other neurology in Detroit
- Bisena BulicaDetroit$900K
- Evanthia BernitsasDetroit$255K
- Andrew RussmanDetroit$118K
- Alex CheblDetroit$68K
- Tobias WalbertDetroit$56K
- Panayiotis VarelasDetroit$48K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.